West Monroe Partners & rMark Bio
While AI is poised to accelerate and optimize Medical Affairs Operations, the readiness to adopt and availability to data to deliver on the ultimate value can be barriers to entry or limit the success of adoption within an organization.
01
The best technologies in the world are used by people. Processes put into motion for sharing insights, increasing collaboration and measuring ROI all mean rethinking more than just your technology. Getting clear on the business value you are delivering with technology will help you achieve measurable impact.
"I use machine learning to recommend personalized KOL content."
"I use machine learning to gain a deeper knowledge of what scientific insights are telling us about opportunities and risk."
02
We help the best pharmaceutical companies in the world innovate and have learned that ultimate success begins with realistically assessing your organization’s current state and evaluating its ability to adopt change across multiple dimensions including data quality, technical expertise and operational maturity.
03
Defining objectives and measurable results early on promotes a data-driven approach to Medical Affairs transformation that can track effectiveness and velocity over time, and helps establishes trust and support in the initiative from key stakeholders to Field Medical teams.
04
A Medical Affairs transformation playbook represents a cross-functional approach that incorporates equal parts change management, data and technology. Led by internal champions, the transformation maintains a consistent message from executives and operational teams across the organization.
05
AI is a continuous process. Launching your AI platform is just the beginning, and overtime – as engagement increases and as data becomes richer – personalized recommendations and insights become more nuanced at an increasingly exponential rate. Strategies are refined and innovation becomes part of the fabric of the organization.
With Cue, teams can plan and prepare for personalized KOL engagements and measure impact throughout the lifecycle of a drug.
Reach out to learn more about how MA(X) can help your organization. We look forward to it.
Jason Smith
920.322.7597
[email protected]
Robert Eubanks
920.322.7596
[email protected]